Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 7Terminated 3Withdrawn 2Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Breast 3Tumor-Agnostic 2Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Glioma 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Therapeutics × CNS × Clear all
NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

Massachusetts General Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡